ArriVent BioPharma (AVBP) Common Equity (2023 - 2026)

ArriVent BioPharma (AVBP) has 4 years of Common Equity data on file, last reported at $324.0 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 59.96% year-over-year to $324.0 million; the trailing twelve-month figure through Mar 2026 stood at $324.0 million (up 59.96% YoY), and the FY2025 full-year result was $307.2 million, up 19.24% from the prior year.
• Common Equity climbed to $324.0 million in Q1 2026, from $307.2 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $324.0 million in Q1 2026 to a low of -$153.2 million in Q4 2023.
• A 4-year average of $156.7 million and a median of $257.7 million in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity soared 427.25% in 2024 and plunged 36.25% in 2025, its largest moves.
• Tracing AVBP's Common Equity over 4 years: stood at -$153.2 million in 2023, then soared by 268.19% to $257.7 million in 2024, then rose by 19.24% to $307.2 million in 2025, then rose by 5.45% to $324.0 million in 2026.
• Business Quant data shows AVBP's Common Equity at $324.0 million in Q1 2026, $307.2 million in Q4 2025, and $305.0 million in Q3 2025.